U.S. Markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
84.94-0.84 (-0.98%)
At close: 4:02PM EDT

85.18 +0.25 (0.30%)
After hours: 4:11PM EDT

People also watch
Full screen
Previous Close85.78
Bid82.68 x 100
Ask86.90 x 900
Day's Range84.90 - 85.56
52 Week Range66.93 - 86.90
Avg. Volume1,695,292
Market Cap196.99B
PE Ratio (TTM)31.01
Earnings DateN/A
Dividend & Yield2.72 (3.17%)
Ex-Dividend Date2017-03-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • Forbes3 hours ago

    Why Gilead Sciences Is Flying High With Kite

    Gilead Sciences has expanded beyond its leading antiviral drug franchises for the treatment of HIV and hepatitis C with the announced acquisition of Kite Pharmaceuticals, giving Gilead a leading edge in cell therapy technology in oncology.

  • Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade
    InvestorPlace6 hours ago

    Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade

    Juno Therapeutics Inc (NASDAQ:JUNO) has a lot going for it off and on the price chart. That doesn’t mean you shouldn’t immunize JUNO stock against the always-real bearish threats. To do that, we’ll explore a fully-hedged, collar-based therapy program. Let me explain.

  • Market Realist8 hours ago

    How Did Novartis’s Established Medicines Perform in 1H17?

    In 1H17, Novartis’s (NVS) Galvus generated revenues of around $596 million compared to $589 million in 1H16.